At the Atopika Institute, we were invited as partners to participate in the SECURE-AD survey. The SECURE-AD Patient survey is designed to help understand how the coronavirus pandemic (COVID-19) affects people with atopic dermatitis (also called atopic eczema). We encourage all people with atopic dermatitis around the world to participate and report their experience with COVID-19 infection using this survey.
The survey is for people with atopic dermatitis who have been diagnosed with COVID-19 or think they have had COVID-19 infection. It is however important that your COVID-19 symptoms started at least two weeks ago, so you can share your personal experience with your COVID-19 infection.
Filling in the survey will take about 10 minutes and consists of questions about yourself, your atopic dermatitis treatment, other conditions/medications and how the COVID-19 infection affected you.
This survey is anonymous and no identifiable information about you will be stored.
More info: https://www.secure-derm.com/
Some direct links for patients:
AD patients survey page: https://www.secure-derm.com/secure-pad/
AD patients FAQ-page: https://www.secure-derm.com/secure-pad-faq/
Supporting partners: https://www.secure-derm.com/ad-partner-organisations/